Akso Health Group ADR
$ 1.39
4.51%
09 Jun - close price
- Market Cap 1,147,984,000 USD
- Current Price $ 1.39
- High / Low $ 1.46 / 1.32
- Stock P/E N/A
- Book Value 0.23
- EPS -0.48
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.68 %
- 52 Week High 2.50
- 52 Week Low 1.07
About
Akso Health Group ADR is a prominent player in the healthcare sector, dedicated to advancing innovative medical solutions and delivering holistic patient care services. Leveraging cutting-edge health technologies, the company actively explores opportunities in telehealth and personalized medicine, underpinned by a robust commitment to research and development. With a resilient business model and a skilled workforce, Akso Health Group offers a compelling investment prospect for institutional investors seeking to engage with the transformative advancements in the healthcare industry.
Analyst Target Price
N/A
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-10 | 2025-11-13 | 2025-08-14 | 2025-06-17 | 2025-03-28 | 2024-07-12 | 2024-04-29 | 2024-01-11 | 2023-12-18 | 2023-07-14 | 2023-06-20 | 2023-02-16 |
| Reported EPS | 0 | 0 | -0.4 | -0.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Estimated EPS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise | 0 | 0 | -0.4 | -0.4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $0.4 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AHG
2026-05-24 15:35:14
Akso Health Group recently switched its independent auditor from Onestop Assurance PAC to CHI-LLTC, effective May 12, 2026. This change is significant given the company's history of small revenue, heavy losses, and ongoing "going concern" warnings. The auditor switch adds another layer of uncertainty to Akso Health's financial reporting and future financing, potentially influencing investor sentiment more than fundamentals in the short term, especially as the company attempts to pivot towards brain-computer interface research.
2026-05-23 11:39:57
Akso Health Group (AHG) recently changed its independent auditor, dismissing Onestop Assurance PAC and appointing CHI-LLTC, a move that could influence investor perception. Despite a stock price decline of 22.73% in the past month, the company's Price-to-Book ratio of 6.6x is considered expensive compared to the broader US Healthcare sector and its peer group. This valuation suggests the market is assigning a full valuation to AHG's balance sheet and future prospects, raising questions about whether the stock is now cheap or if the market has already factored in anticipated growth.
2026-05-15 01:39:49
Akso Health Group (AHG) has announced a change in its independent auditor, replacing Onestop Assurance PAC with CHI-LLTC, effective May 12, 2026. This transition follows two fiscal years without adverse opinions or disagreements from the previous auditor, indicating an internal decision rather than accounting issues. TipRanks' AI Analyst, Spark, rates AHG as "Neutral" due to profitability challenges, revenue instability, negative momentum, and a weak valuation.
2026-05-13 20:40:12
Akso Health Group (AHG) has replaced its independent auditor, dismissing Onestop Assurance PAC and appointing CHI-LLTC, effective May 12, 2026. The previous auditor issued no adverse opinions or disagreements, and Akso stated they did not consult CHI-LLTC on accounting matters prior to the change, indicating an internal decision. TipRanks' AI Analyst, Spark, rates AHG as "Neutral" due to profitability and revenue stability challenges, negative technical momentum, and a weak valuation.
2026-05-07 10:10:22
Akso Health Group (AHG) announced an early-stage Brain-Computer Interface (BCI) research and development program, focusing on high-resolution neural sensing and AI decoding. While this BCI initiative could reshape its long-term investment narrative, the company still faces immediate financial challenges like extending its cash runway and addressing going concern flags. Investors also need to consider potential overvaluation and the high-uncertainty nature of BCI development.
2026-05-07 10:09:44
Akso Health Group announced in April 2026 that it had initiated a next-generation Brain-Computer Interface (BCI) research and development program, focusing on advanced neural sensing, AI neural decoding, and interface design, with pending patent applications. While the BCI initiative adds a high-concept element to the company's long-term potential, its immediate challenges include financial instability, a short cash runway, and a fluctuating share price. Investors are cautioned to consider the early-stage nature and high uncertainty of BCI, alongside current financial risks and a potential overvaluation, despite the long-term innovation narrative.
